The present invention relates to mildronate for use in the prevention or treatment of ophthalmic disorders associated with an abnormal cell proliferation and/or ocular neovascularization, such as for example neovascular glaucoma, and/or proliferative vitreoretinopathy. The administration is preferably by intravitreal injection.
